|MolMed S p A -- Germany Stock|| |
EUR 0.53 0.01 1.85%
Director Business Development & Investor Relations
Dr. Holger Neecke Ph.D. serves as Director of Business Development Investor Relations at Molecular Medicine S.p.A. He joined the Company in October 2001. Before that he worked at Biopolo Scrl where he developed and evaluated business plans for startup companies. At the Company he has acquired experience in biotech business development particularly by structuring negotiating and finalizing license agreements with pharmacy and biotech companies and institutions in Europe Japan and the United States. He gained a degree in Molecular Biology from Universitaet Basel a Masters of Business Administration from Universita Commerciale Luigi Bocconi and a Doctorate in Philosophy in Genetics from Universita degli Studi di Milano.
39 02 21 27 71 http://www.molmed.com
The company has return on total asset (ROA)
of (18.1) %
which means that it has lost $18.1 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (61.21) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 964 K in total debt with debt to equity ratio (D/E) of 6.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. MolMed S p A has Current Ratio of 1.37 which is within standard range for the sector.
MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of anticancer therapies. MolMed S.p.A. was founded in 1996 and is headquartered in Milan, Italy. MolMed S is traded on Frankfurt Stock Exchange in Germany.MolMed S p A (4HW) is traded on Frankfurt Stock Exchange in Germany. It is located in Via Olgettina, 58 and employs 23 people.